A potential blood test can distinguish ME/chronic fatigue syndrome with great accuracy, after years of medical uncertainty.

Shield’s FDA-approved blood test drives cancer screening growth, pricing power, and cash-flow upside. Click for this GH ...

Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score ...

Single-cell research of patients’ immune cells to guide future treatments: Dr Arivusudar John: Shardul Nautiyal, Mumbai Friday, January 16, 2026, 08:00 Hrs [IST] Single-Cell Ana ...

QT Imaging Holdings, Inc. ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today ...

HOUSTON, TEXAS / ACCESS Newswire / January 20, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for ar ...

AI Nose commercial deployment accelerates in 2026 with dual-engine architecture, industrial expansion, and recurring SaaS revenue modelNew Trusval agreement commits to minimum 600-unit deployment, pos ...

The demonstrator model, based on Madrid urban conditions, is able to calculate yields but can also be used to evaluate alternative maximum power point tracking (MPPT) algorithms. The team combined ...

Researchers from the Faculty of Engineering at The University of Hong Kong (HKU) have developed two innovative deep-learning ...

CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth ...

The MarketWatch News Department was not involved in the creation of this content. CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune ...

Record full year 2025 revenue, an increase of at least 19% over 2024 AVISE CTD trailing 12-month (TTM) ASP expansion by at least $30 compared to 2024 AVISE CTD test volume growth of at least 13,000, ...